.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

UBS
Covington
Novartis
Harvard Business School
Express Scripts
Cerilliant
Teva
Deloitte
Julphar
Fish and Richardson

Generated: November 22, 2017

DrugPatentWatch Database Preview

Telavancin hydrochloride - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for telavancin hydrochloride and what is the scope of telavancin hydrochloride patent protection?

Telavancin hydrochloride
is the generic ingredient in one branded drug marketed by Theravance Biopharma and is included in one NDA. There are eleven patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Telavancin hydrochloride has one hundred and twenty-seven patent family members in thirty-five countries and twelve supplementary protection certificates in eleven countries.

Two suppliers are listed for this compound.

Pharmacology for telavancin hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Theravance Biopharma
VIBATIV
telavancin hydrochloride
POWDER;IV (INFUSION)022110-001Sep 11, 2009DISCNYesNo► Subscribe► SubscribeY ► Subscribe
Theravance Biopharma
VIBATIV
telavancin hydrochloride
POWDER;IV (INFUSION)022110-001Sep 11, 2009DISCNYesNo► Subscribe► SubscribeY ► Subscribe
Theravance Biopharma
VIBATIV
telavancin hydrochloride
POWDER;IV (INFUSION)022110-001Sep 11, 2009DISCNYesNo► Subscribe► SubscribeYY ► Subscribe
Theravance Biopharma
VIBATIV
telavancin hydrochloride
POWDER;IV (INFUSION)022110-001Sep 11, 2009DISCNYesNo► Subscribe► SubscribeY ► Subscribe
Theravance Biopharma
VIBATIV
telavancin hydrochloride
POWDER;IV (INFUSION)022110-001Sep 11, 2009DISCNYesNo► Subscribe► Subscribe ► Subscribe
Theravance Biopharma
VIBATIV
telavancin hydrochloride
POWDER;IV (INFUSION)022110-002Sep 11, 2009RXYesYes► Subscribe► SubscribeYY ► Subscribe
Theravance Biopharma
VIBATIV
telavancin hydrochloride
POWDER;IV (INFUSION)022110-002Sep 11, 2009RXYesYes► Subscribe► SubscribeY ► Subscribe
Theravance Biopharma
VIBATIV
telavancin hydrochloride
POWDER;IV (INFUSION)022110-001Sep 11, 2009DISCNYesNo► Subscribe► SubscribeYY ► Subscribe
Theravance Biopharma
VIBATIV
telavancin hydrochloride
POWDER;IV (INFUSION)022110-002Sep 11, 2009RXYesYes► Subscribe► SubscribeY ► Subscribe
Theravance Biopharma
VIBATIV
telavancin hydrochloride
POWDER;IV (INFUSION)022110-002Sep 11, 2009RXYesYes► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: telavancin hydrochloride

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,859,506Glycopeptide phosphonate derivatives► Subscribe
7,244,705Polyacid glycopeptide derivatives► Subscribe
7,157,554Glycopeptide carboxy-saccharide derivatives► Subscribe
6,620,781 Glycopeptide carboxy-saccharide derivatives► Subscribe
6,831,150 Reductive alkylation process► Subscribe
6,872,804 Glycopeptide disulfide and thioester derivatives► Subscribe
6,906,031 Polyacid glycopeptide derivatives► Subscribe
6,903,070 Glycopeptide carboxy-saccharide derivatives► Subscribe
7,026,288Pharmaceutical compositions containing a glycopeptide antibiotic and a cyclodextrin► Subscribe
8,003,755Hydrochloride salts of a glycopeptide phosphonate derivative► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: telavancin hydrochloride

Country Document Number Estimated Expiration
Portugal2495251► Subscribe
Australia5930301► Subscribe
South Korea100768488► Subscribe
Spain2477268► Subscribe
Canada2726967► Subscribe
Egypt26726► Subscribe
Poland359419► Subscribe
Eurasian Patent Organization200300050► Subscribe
TaiwanI342312► Subscribe
Spain2311014► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: TELAVANCIN HYDROCHLORIDE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
11/037Ireland► SubscribePRODUCT NAME: TELAVANCIN, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, INCLUDING TELAVANCIN HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/11/705/001-002 20110902
7Finland► Subscribe
C0051France► SubscribePRODUCT NAME: TELAVANCINE; REGISTRATION NO/DATE: EU/1/11/705/001-002 20110902
C/GB11/056United Kingdom► SubscribePRODUCT NAME: TELAVANCIN, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, INCLUDING TELAVANCIN HYDROCHLORIDE; REGISTERED: UK EU/1/11/705/001 20110906; UK EU/1/11/705/002 20110906
2011 00033Denmark► Subscribe
908Luxembourg► Subscribe91908, EXPIRES: 20260501
2012002Lithuania► SubscribePRODUCT NAME: TELAVANCINUM; REGISTRATION NO/DATE: EU/1/11/705/001, 2011 09 02 EU/1/11/705/002 20110902
00507Netherlands► SubscribePRODUCT NAME: TELAVANCINE, OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, INCLUSIEF TELAVANCINE HYDROCLORIDE; REGISTRATION NO/DATE: EU/1/11/705/001 - 002 20110902
2012002,C1292612Lithuania► SubscribePRODUCT NAME: TELAVANCINUM; REGISTRATION NO/DATE: EU/1/11/705/001, 2011 09 02 EU/1/11/705/002 20110902
2011100062Germany► SubscribePRODUCT NAME: TELAVANCIN ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ HIERVON, EINSCHLIESSLICH TELAVANCINHYDROCHLORID; REGISTRATION NO/DATE: EU/1/11/705/001-002 20110902
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Moodys
Farmers Insurance
UBS
Fuji
Fish and Richardson
Express Scripts
Chubb
Cipla
Merck
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot